Predictive biomarkers for immunotherapy in lung cancer: perspective from the international association for the study of lung cancer pathology committee
M Mino-Kenudson, K Schalper, W Cooper… - Journal of Thoracic …, 2022 - Elsevier
Immunotherapy including immune checkpoint inhibitors (ICIs) has become the backbone of
treatment for most lung cancers with advanced or metastatic disease. In addition, they have …
treatment for most lung cancers with advanced or metastatic disease. In addition, they have …
Quantitative multiplexed imaging technologies for single-cell analysis to assess predictive markers for immunotherapy in thoracic immuno-oncology: promises and …
The past decade has witnessed a revolution in cancer treatment by the shift from
conventional drugs (chemotherapies) towards targeted molecular therapies and immune …
conventional drugs (chemotherapies) towards targeted molecular therapies and immune …
Association of machine learning–based assessment of tumor-infiltrating lymphocytes on standard histologic images with outcomes of immunotherapy in patients with …
Importance Currently, predictive biomarkers for response to immune checkpoint inhibitor
(ICI) therapy in lung cancer are limited. Identifying such biomarkers would be useful to refine …
(ICI) therapy in lung cancer are limited. Identifying such biomarkers would be useful to refine …
Atezolizumab plus bevacizumab as first-line treatment for patients with metastatic nonsquamous non–small cell lung cancer with high tumor mutation burden: a …
M Provencio, AL Ortega, J Coves-Sarto, V Calvo… - JAMA …, 2023 - jamanetwork.com
Importance Antiangiogenic drug combinations with anti–programmed cell death 1 protein
and anti–programmed cell death 1 ligand 1 (PD-L1) agents are a novel treatment option for …
and anti–programmed cell death 1 ligand 1 (PD-L1) agents are a novel treatment option for …
KRAS mutations in solid tumors: characteristics, current therapeutic strategy, and potential treatment exploration
Y Yang, H Zhang, S Huang, Q Chu - Journal of Clinical Medicine, 2023 - mdpi.com
Kristen rat sarcoma (KRAS) gene is one of the most common mutated oncogenes in solid
tumors. Yet, KRAS inhibitors did not follow suit with the development of targeted therapy, for …
tumors. Yet, KRAS inhibitors did not follow suit with the development of targeted therapy, for …
Transcriptomic correlates of tumor cell PD-L1 expression and response to nivolumab monotherapy in metastatic clear cell renal cell carcinoma
Purpose: PD-L1 expression on tumor cells (TC) is associated with response to anti-PD-1-
based therapies in some tumor types, but its significance in clear cell renal cell carcinoma …
based therapies in some tumor types, but its significance in clear cell renal cell carcinoma …
Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit
SA Tomlins, NA Khazanov, BJ Bulen… - Communications …, 2023 - nature.com
Abstract Background Anti-PD-1 and PD-L1 (collectively PD-[L] 1) therapies are approved for
many advanced solid tumors. Biomarkers beyond PD-L1 immunohistochemistry …
many advanced solid tumors. Biomarkers beyond PD-L1 immunohistochemistry …
[HTML][HTML] Ferroptosis patterns and tumor microenvironment infiltration characterization in bladder cancer
QD Xia, JX Sun, CQ Liu, JZ Xu, Y An, MY Xu… - Frontiers in Cell and …, 2022 - frontiersin.org
Background: Ferroptosis is a unique iron-dependent form of cell death and bladder cancer
(BCa) is one of the top ten most common cancer types in the world. However, the role of …
(BCa) is one of the top ten most common cancer types in the world. However, the role of …
LC-MS/MS Based volatile organic compound biomarkers analysis for early detection of lung cancer
Simple Summary In our work, we described and proposed a novel LC-MS/MS based
approach for early lung cancer screening based on the VOC marker. Through this approach …
approach for early lung cancer screening based on the VOC marker. Through this approach …
Outcome-Supervised Deep Learning on Pathologic Whole Slide Images for Survival Prediction of Immunotherapy in Patients with Non–Small Cell Lung Cancer
B Li, L Yang, H Zhang, H Li, C Jiang, Y Yao, S Cheng… - Modern Pathology, 2023 - Elsevier
Abstract Although programmed death-(ligand) 1 (PD-(L) 1) inhibitors are marked by durable
efficacy in patients with non–small cell lung cancer (NSCLC), approximately 60% of the …
efficacy in patients with non–small cell lung cancer (NSCLC), approximately 60% of the …